ArticleTheranostics2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- A Degradomic Landscape of Proteolytic Remodeling in Melanoma Lung Metastasis.Journal of proteome research · 2026Article
- The contribution of phenolic endocrine-disrupting chemicals to breast cancer risk: A comprehensive bioinformatics analysis.Scientific reports · 2026Article
- Identification and validation of a refined CAF-Associated diagnostic signature in breast cancer.Scientific reports · 2026Article
- The role of exercise-induced myokines in cancer-associated inflammation and immune regulation: mechanisms and prospects.Frontiers in sports and active living · 2026Review
- Exercise-induced myokines and the muscle-tumor axis in obesity-driven gynecological cancers: a narrative review.Frontiers in oncology · 2026Review
- Integration of Single-cell and Bulk Transcriptome Analyses Unravels a Macrophage-based Gene Signature for Prognostication and Treatment in Triple-negative Breast Cancer.International journal of medical sciences · 2026Article
- Design and Preclinical Evaluation of FirstJournal of medicinal chemistry · 2025Article
- SPARC-modified mesenchymal stem cells promote recovery of β-cells and insulin secretion by calcium ion homeostasis.Stem cell research & therapy · 2025Article
- Collagen-Based Tumor Spheroid Model for Investigating Tumor-Macrophage Interactions through Extracellular Matrix Remodeling.bioRxiv : the preprint server for biology · 2025Article
- Identifying protease-activated targets and exploring therapeutic applications.Expert opinion on therapeutic targets · 2025Review
- CAFs exosomal circFOXO1 promotes TNBC autophagy and radioresistance via miR-27a-3p/BNIP3 axis.Scientific reports · 2025Article
- Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers.Seminars in cancer biology · 2025Review
- Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Paxillin promotes the invasion and migration of polyploid giant cancer cells with daughter cells after arsenic trioxide treatment by regulating the expression of cathepsin B/D.Journal of Cancer · 2025Article
- Article
- Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis.Molecular metabolism · 2024Article
- A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.Journal for immunotherapy of cancer · 2024Article
- Characterization of cancer-associated fibroblasts (CAFs) and development of a CAF-based risk model for triple-negative breast cancer.Cancer cell international · 2023Article
- SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.International journal of cancer · 2023Article
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 4 countries.
Lindsay B AlcarazIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Aude MallavialleIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Timothée DavidIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Danielle DerocqIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Frédéric DelolmeUniversity of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.
Cindy DieryckxUniversity of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.
Caroline MolleviBiometry department, ICM, Montpellier, France.
Florence Boissière-MichotTranslational Research Unit, ICM, Montpellier, France.
Joëlle Simony-LafontaineTranslational Research Unit, ICM, Montpellier, France.
Stanislas Du ManoirIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Pitter F HuesgenUniversity of British Columbia, Faculty of Dentistry, Centre for Blood Research, British Columbia, V6T 1Z3, Canada.
Christopher M OverallUniversity of British Columbia, Faculty of Dentistry, Centre for Blood Research, British Columbia, V6T 1Z3, Canada.
Sophie Tartare-DeckertCôte d'Azur University, Inserm, C3M, Nice, France.
William JacotIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Thierry ChardèsIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Séverine GuiuIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Pascal RogerIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Thomas ReinheckelInstitute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany.
Catherine MoaliUniversity of Lyon, CNRS UMR5305, Tissue Biology and Therapeutic Engineering Laboratory (LBTI), F-69367 Lyon, France.
Emmanuelle Liaudet-CoopmanIRCM, INSERM U1194, Univ Montpellier, ICM, Montpellier, France.
Inserm · FRUniversité Claude Bernard Lyon 1 · FRInstitut de Recherche en Cancérologie de Montpellier · FRUniversity of British Columbia · CAUniversity of Freiburg · DEZimmer Biomet (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Tumor MicroenvironmentAmino Acid SequenceAnimalsBinding SitesCathepsin DCell AdhesionExtracellular MatrixFemaleFibroblastsGene Expression Regulation, NeoplasticHumansHydrogen-Ion ConcentrationMammary Neoplasms, ExperimentalMiceMice, KnockoutMice, TransgenicCathepsin DCtsd protein, mouseNeoplasm ProteinsOsteonectinPeptide FragmentsSPARC protein, humanbioactive fragmentECMmatricellular proteinproteaseTNBCtumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.